In the past week, bluebird bio named new leaders after its acquisition, Dyne secured a debt deal and ProFound Therapeutics ...

ProFound Therapeutics, a company pioneering the expanded human proteome to develop medicines, has announced a four-year ...

Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.

Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

ProFound Therapeutics enters multi-year strategic collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease: Cambridge, Massachusetts Frida ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease ProFound to receive $25M in upfront and near ...

Organizations that delay systematic AI deployment risk being left behind by competitors who have already mastered the transition from experimentation to execution.

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Chip Wilson, the visionary entrepreneur who fundamentally reshaped the world of athletic apparel with Lululemon, is now ...

Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

Swiss pharma giant Novartis has announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx (secukinumab ...